Suppr超能文献

糖皮质激素性骨质疏松:临床医生须知

Glucocorticoid-induced osteoporosis: Insights for the clinician.

作者信息

Hayat Shakaib, Magrey Marina N

机构信息

MetroHealth Medical Center, Cleveland, OH.

Fellowship Program Director, Department of Rheumatology, MetroHealth Medical Center, Cleveland, OH

出版信息

Cleve Clin J Med. 2020 Jun 30;87(7):417-426. doi: 10.3949/ccjm.87a.19039.

Abstract

Glucocorticoids cause significant bone loss, predominantly affecting trabecular bone, with consequent fragility fractures. The risk of fractures is related to the dose and duration of glucocorticoid use, but an increased risk may be observed even at low doses and even in the first month of treatment. Steps to prevent or treat osteoporosis should be considered in all patients who take the equivalent of prednisone at a dose of 2.5 mg or more per day for 3 or more months.

摘要

糖皮质激素会导致显著的骨质流失,主要影响小梁骨,进而引发脆性骨折。骨折风险与糖皮质激素的使用剂量和疗程有关,但即使是低剂量使用,甚至在治疗的第一个月,骨折风险也可能增加。对于所有每天服用相当于泼尼松2.5毫克或更高剂量且持续3个月或更长时间的患者,都应考虑采取预防或治疗骨质疏松症的措施。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验